HERZLIYA, Israel--(BUSINESS WIRE)--Tissera, Inc. (OTCBB:TSSR) reports the achievement of a significant milestone in its ongoing large animal diabetic model experiments of pancreatic xenotransplantation, designed for the future treatment of insulin-dependent (type I) diabetes mellitus.
